![[Key Takeaways from CDDF Live Webinar – “Compassionate Use and EAP for Cancer Drugs – From Fragmentation to a Common Framework in Europe under the New Legislation” (26 October 2026)]](https://cddf.org/wp-content/uploads/2026/10/CDDF-2026-Oct-Webinar-Compassionate-Use-Key-Takeaways-1-400x250.jpg)
[Key Takeaways from CDDF Live Webinar – “Compassionate Use and EAP for Cancer Drugs – From Fragmentation to a Common Framework in Europe under the New Legislation” (26 October 2026)]
The CDDF is pleased to share the key takeaways from our live webinar – “Compassionate Use and EAP for Cancer Drugs – From Fragmentation to a Common Framework in Europe under the New Legislation” held on 26 October 2026. This webinar includes presentations by François...
Multi-stakeholder Interview: Get an Inside Look at the CDDF Workshop on HTA in Cancer Drug Development
We are excited to share interview clips featuring a diverse group of stakeholders at CDDF & EORTC Joint Workshop on HTA in Cancer Drug Development. Held in Brussels on 5-6 October 2026, the meeting highlighted multi-stakeholder collaboration as the cornerstone of...
![🔔 [Executive Summary Published: CDDF & EORTC Joint Workshop on HTA in Cancer Drug Development]](https://cddf.org/wp-content/uploads/2026/10/Thumbnail-image-400x250.jpg)
🔔 [Executive Summary Published: CDDF & EORTC Joint Workshop on HTA in Cancer Drug Development]
We are delighted to announce that the executive summary of the CDDF & EORTC joint workshop on "Health Technology Assessment in Cancer Drug Development" has been published today. This multi-stakeholder workshop was held on 5-6 October 2026 in Brussels (BE) to help...
CDDF NEW WHITEPAPER: Improving Patient Access to New Treatment Modalities in European Cancer Care
We are delighted to announce that CDDF’s new whitepaper, Improving Patient Access to New Treatment Modalities in European Cancer Care, has been published in the Journal of Market Access & Health Policy this month. This paper highlights practical challenges and...
Celebrating 25 Years of the Cancer Drug Development Forum (CDDF)
This month, CDDF marks 25 years of turning hope into...
Call for Case Studies & Panelists/Session Chairs: Upcoming ACT-EU Workshop on Multiplicity in Confirmatory Two-Arm and Platform Trials
Following a recent MSP AG discussion, stakeholders are invited to contribute for the upcoming ACT-EU workshop on multiplicity in confirmatory two-arm and platform trials, taking place on 27 November 2026 at the EMA in Amsterdam. 🔍 How you can contribute: 1️⃣ Present a...
CDDF & WECAN Foundation: Memorandum of Understanding
🔔 📢 We are delighted to announce that CDDF and the WECAN Foundation (Workgroup of European Cancer Patient Advocacy Networks) have formalized our long-standing collaboration through a Memorandum of Understanding. This partnership will enable the organizations to work...
![[🔔 📊 Participate in the ENCePP Survey on AI in Pharmacoepidemiology & Pharmacovigilance]](https://cddf.org/wp-content/uploads/2026/07/Capture-400x250.jpg)
[🔔 📊 Participate in the ENCePP Survey on AI in Pharmacoepidemiology & Pharmacovigilance]
The ENCePP Working Group on Artificial Intelligence in Pharmacoepidemiology and Pharmacovigilance invite stakeholders to contribute to a survey examining the perception and use of artificial intelligence (AI) tools across Pharmacoepidemiology (PE) and...
![📢 🔔 [News from EMA – Public Consultation on Its Draft Recommendations]](https://cddf.org/wp-content/uploads/2026/07/EMA-News-5-400x250.jpg)
📢 🔔 [News from EMA – Public Consultation on Its Draft Recommendations]
The European Network of Paediatric Research at the EMA (EnprEMA) has launched a public consultation on its draft recommendations: "Cross-border access to paediatric clinical trials in Europe: preventing language exclusion." 📄 About the draft recommendations The draft...